Harrigan PR - Search Results

1

HIV antiviral drug resistance: patient comprehension.

Racey CS, Zhang W, Brandson EK, Fernandes KA, Tzemis D, Harrigan PR, Montaner JS, Barrios R, Toy J, Hogg RS. Racey CS, et al. Among authors: harrigan pr. AIDS Care. 2010 Jul;22(7):816-26. doi: 10.1080/09540120903431355. AIDS Care. 2010. PMID: 20635245

2

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.

Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, Brumme CJ, Montaner JS, Harrigan PR. Wood E, et al. Among authors: harrigan pr. AIDS. 2005 Jul 22;19(11):1189-95. doi: 10.1097/01.aids.0000176219.48484.f1. AIDS. 2005. PMID: 15990572

3

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.

Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS. Phillips E, et al. Among authors: harrigan pr. AIDS. 2007 Jul 31;21(12):1561-8. doi: 10.1097/QAD.0b013e3282170a9d. AIDS. 2007. PMID: 17630551

4

Epidemiology of treatment failure: a focus on recent trends.

Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS. Hull MW, et al. Among authors: harrigan pr. Curr Opin HIV AIDS. 2009 Nov;4(6):467-73. doi: 10.1097/COH.0b013e328331d353. Curr Opin HIV AIDS. 2009. PMID: 20048712 Review.

5

Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010.

Cescon A, Kanters S, Brumme CJ, Lepik KJ, Forrest JI, Hull M, Samji H, Nosyk B, Harrigan PR, Hogg RS, Montaner JS. Cescon A, et al. Among authors: harrigan pr. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):107-14. doi: 10.1097/QAI.0b013e3182a8efc3. J Acquir Immune Defic Syndr. 2014. PMID: 23978999 Free PMC article.

6

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.

Lima VD, Reuter A, Harrigan PR, Lourenço L, Chau W, Hull M, Mackenzie L, Guillemi S, Hogg RS, Barrios R, Montaner JS. Lima VD, et al. Among authors: harrigan pr. AIDS. 2015 Sep 10;29(14):1871-82. doi: 10.1097/QAD.0000000000000790. AIDS. 2015. PMID: 26165354 Free PMC article.

7

Emergent drug resistance with integrase strand transfer inhibitor-based regimens.

Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, Lima VD, Guillemi S, Montaner JSG, Barrios R. Lepik KJ, et al. Among authors: harrigan pr. AIDS. 2017 Jun 19;31(10):1425-1434. doi: 10.1097/QAD.0000000000001494. AIDS. 2017. PMID: 28375875

8

A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015.

Olding M, Enns B, Panagiotoglou D, Shoveller J, Harrigan PR, Barrios R, Kerr T, Montaner JSG, Nosyk B. Olding M, et al. Among authors: harrigan pr. J Int AIDS Soc. 2017 Sep 19;20(1):21941. doi: 10.7448/IAS.20.1.21941. J Int AIDS Soc. 2017. PMID: 28953322 Free PMC article. Review.

9

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Among authors: harrigan pr. AIDS. 2002 Sep 27;16(14):1929-33. doi: 10.1097/00002030-200209270-00010. AIDS. 2002. PMID: 12351953

10

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. AIDS. 2003 Mar 28;17(5):711-20. doi: 10.1097/00002030-200303280-00009. AIDS. 2003. PMID: 12646794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters